Simvastatin for Recurrent Acute and Chronic Pancreatitis
This study is looking at whether simvastatin, a common cholesterol-lowering medication, can improve the quality of life for people with recurrent acute pancreatitis (RAP) or chronic pancreatitis (CP). Currently, there are no specific treatments for these conditions, which can cause ongoing abdominal pain. Researchers want to see if simvastatin can help reduce pain and improve overall health in patients aged 18 to 75. This is a pilot study, meaning it's a smaller, initial step to see if a larger study would be worthwhile. The main goal is to check if it's practical and acceptable to test simvastatin's effects on your health-related quality of life over 12 months.
- Study design
- This is a pilot, double-blind study where 90 participants will be randomly assigned to receive either simvastatin or a placebo (an inactive pill that looks like simvastatin).
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months to measure the effects of simvastatin on their health-related quality of life.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
At a glance
Conditions
Where it's being run
5 sites across 3 statesStudy leadership
- Stephen Pandol, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Examine the feasibility and acceptability of testing the effect of simvastatin on health-related quality of life outcomes in patients with recurrent acute and chronic pancreatitis.End of study (12 Months)
A priori thresholds to evaluate feasibility are: 50% enrollment, \<15% attrition, \>75% adherence with doses, \<20% side effects. A score of \>75% acceptability ratings per an "Acceptability Form" that will be provided during the last visit will be used to gauge the general acceptability of the intervention (Simvastatin or Placebo) and study procedures to each participating subject.